

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Joseph William EPSTEIN, and Semiramis AYRAL-KALOUSTIAN;

For: 3-SUBSTITUTED-3-(SUBSTITUTEDSULFONYL OR
SULFANYL)PYRROLIDINE-2,4-DIONES USEFUL FOR INHIBITION OF
FARNESYL-PROTEIN TRANSFERASE.

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☒ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Serial Number 10/227,215 filed on August 23, 2002 of Joseph William Epstein, et al. for 3-SUBSTITUTED-3-(SUBSTITUTEDSULFONYL OR SULFANYL)PYRROLIDINE-2,4-DIONES USEFUL FOR INHIBITION OF FARNESYL-PROTEIN TRANSFERASE .

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU673382474US addressed to the Commissioner for Patents, Washington, DC 20231.

Date

September 26, 2003

Daniel B. Moran

Daniel B. Moran

3. ☐ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application is enclosed.
4. ☐ Concise Explanation
Documents cited above which are not in the English Language
a. ☐ have been explained in the specification.
b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.



Daniel B. Moran

Reg. No. 41,204

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-2224

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
Examiner Name		Joseph William Epstein			
Sheet	1	of	1	Attorney Docket Number	AM100079 D2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.					

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	95/24400		Jay Edward WROBEL	09-14-1995		<input type="checkbox"/>
	3.	WO	97/36605		Samuel L. GRAHAM	10-09-1997		<input type="checkbox"/>
	4.	WO	98/07692		Francis Thomas BOYLE	02-26-1998		<input type="checkbox"/>
	5.	WO	99/05117		Jin LEE	02-04-1999		<input type="checkbox"/>
	6.	WO	01/85685		Gil MARTINEZ	11-15-2001		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	7.	J.L. BOS, Cancer Res., 1989, 49, 4682.	<input type="checkbox"/>
	8.	P.J. CASEY, P.A. SOLSKI, C.J. DER, J.E. BUSS, Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 8323.	<input type="checkbox"/>
	9.	J.F. HANCOCK, H. PATERSON, C.J. MARSHALL, Cell, 1990, 63, 133	<input type="checkbox"/>
	10.	ZASK, et al., J. Med. Chem., 1990, 33, 1418-1423.	<input type="checkbox"/>
	11.	P. SKEHAN, R. STORENG, D. SCUDIERO, A. MONKS, J. MC MOHAN, D. VISTICA, J. WARREN, J. BOKESH, S. KENNEY, M.R. BOYD, J. Natl. Cancer Instit., 1990, 82(13), 1107-1112.	<input type="checkbox"/>
	12.	L.V. RUBINSTEIN, R.H. SHOEMAKER, K.D. PAULL, R.M. SIMON, S. TOSINI, P. SKEHAN, D.A. SCUDIERO, A. MONKS, M.R. BOYD, J. Natl. Cancer Instit., 1990, 82(13), 1113-1118.	<input type="checkbox"/>
	13.	J.F. MOOMAW, P.J. CASEY, J. Biol. Chem., 1992, 267, 17438-17443.	<input type="checkbox"/>
	14.	M.A. GARCIA, et al., J. Biol. Chem., 1993, 268, 18415-18420.	<input type="checkbox"/>
	15.	G.L. BOLTON, J.S. SEBOLT-LEOPOLD, J.C. HODGES; Annu. Rep. Med. Chem., 1994, 29, 165.	<input type="checkbox"/>
	16.	R.J.A. GRAND in "New Molecular Targets in Cancer Chemotherapy", J.D. Kerr and P. Workman, Eds. CRC Press, Boca Raton, FL., 1994, P. 97.	<input type="checkbox"/>
	17.	G.L. JAMES, M.S. BROWN, J.L. GOLDSTEIN, Methods in Enzymology, 1995, 255, 38-46.	<input type="checkbox"/>
	18.	M.R. BOYD, K.D. PAULL, Drug Development Res., 1995, 34, 91-109.	<input type="checkbox"/>
	19.	S.P. FRICKER, R.G. BUCKLEY, Anticancer Research, 1996, 16, 3755-3760.	<input type="checkbox"/>
	20.	S. AYRAL-KALOUSTIAN, J.S. SKOTNICKI, Annu. Rep. Med. Chem., 1996, 31, 171.	<input type="checkbox"/>
	21.	T.M. WILLIAMS, Exp. Opin. Ther. Patents, 1998, 8, 553.	<input type="checkbox"/>
	22.	SCH-66336, Pharmaprojects, 1998, No. 5128	<input type="checkbox"/>
	23.	R-115777, Pharmaprojects, 1998, No. 5532.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Group Art Unit	
Examiner Name				Joseph William Epstein	
Sheet	1	of	1	Attorney Docket Number	
AM100079 D2					

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	95/24400		Jay Edward WROBEL	09-14-1995		<input type="checkbox"/>
	3.	WO	97/36605		Samuel L. GRAHAM	10-09-1997		<input type="checkbox"/>
	4.	WO	98/07692		Francis Thomas BOYLE	02-26-1998		<input type="checkbox"/>
	5.	WO	99/05117		Jin LEE	02-04-1999		<input type="checkbox"/>
	6.	WO	01/85685		Gil MARTINEZ	11-15-2001		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	7.	J.L. BOS, Cancer Res., 1989, 49, 4682.	<input type="checkbox"/>
	8.	P.J. CASEY, P.A. SOLSKI, C.J. DER, J.E. BUSS, Proc. Natl. Acad. Sci. U.S.A., 1989, 86, 8323.	<input type="checkbox"/>
	9.	J.F. HANCOCK, H. PATERSON, C.J. MARSHALL, Cell, 1990, 63, 133	<input type="checkbox"/>
	10.	ZASK, et al., J. Med. Chem., 1990, 33, 1418-1423.	<input type="checkbox"/>
	11.	P. SKEHAN, R. STORENG, D. SCUDIERO, A. MONKS, J. MC MOHAN, D. VISTICA, J. WARREN, J. BOKESH, S. KENNEY, M.R. BOYD, J. Natl. Cancer Instit., 1990, 82(13), 1107-1112.	<input type="checkbox"/>
	12.	L.V. RUBINSTEIN, R.H. SHOEMAKER, K.D. PAULL, R.M. SIMON, S. TOSINI, P. SKEHAN, D.A. SCUDIERO, A. MONKS, M.R. BOYD, J. Natl. Cancer Instit., 1990, 82(13), 1113-1118.	<input type="checkbox"/>
	13.	J.F. MOOMAW, P.J. CASEY, J. Biol. Chem., 1992, 267, 17438-17443.	<input type="checkbox"/>
	14.	M.A. GARCIA, et al., J. Biol. Chem., 1993, 268, 18415-18420.	<input type="checkbox"/>
	15.	G.L. BOLTON, J.S. SEBOLT-LEOPOLD, J.C. HODGES; Annu. Rep. Med. Chem., 1994, 29, 165.	<input type="checkbox"/>
	16.	R.J.A. GRAND in "New Molecular Targets in Cancer Chemotherapy", J.D. Kerr and P. Workman, Eds. CRC Press, Boca Raton, FL., 1994, P. 97.	<input type="checkbox"/>
	17.	G.L. JAMES, M.S. BROWN, J.L. GOLDSTEIN, Methods in Enzymology, 1995, 255, 38-46.	<input type="checkbox"/>
	18.	M.R. BOYD, K.D. PAULL, Drug Development Res., 1995, 34, 91-109.	<input type="checkbox"/>
	19.	S.P. FRICKER, R.G. BUCKLEY, Anticancer Research, 1996, 16, 3755-3760.	<input type="checkbox"/>
	20.	S. AYRAL-KALOUSTIAN, J.S. SKOTNICKI, Annu. Rep. Med. Chem., 1996, 31, 171.	<input type="checkbox"/>
	21.	T.M. WILLIAMS, Exp. Opin. Ther. Patents, 1998, 8, 553.	<input type="checkbox"/>
	22.	SCH-66336, Pharmaprojects, 1998, No. 5128	<input type="checkbox"/>
	23.	R-115777, Pharmaprojects, 1998, No. 5532.	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.